Barclays PLC lessened its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 37.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,253 shares of the company's stock after selling 50,453 shares during the quarter. Barclays PLC's holdings in BioNTech were worth $9,887,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Planning Capital Management Corp boosted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. boosted its position in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after buying an additional 388 shares during the period. GAMMA Investing LLC grew its holdings in BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Daiwa Securities Group Inc. increased its position in BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock valued at $155,000 after acquiring an additional 1,562 shares during the period. Finally, Caprock Group LLC bought a new position in shares of BioNTech during the second quarter valued at $206,000. Institutional investors own 15.52% of the company's stock.
BioNTech Stock Up 2.8 %
Shares of BNTX stock traded up $3.17 on Tuesday, reaching $117.39. 655,397 shares of the company were exchanged, compared to its average volume of 808,687. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a 50-day moving average of $113.66 and a 200-day moving average of $100.66. The company has a market cap of $27.91 billion, a price-to-earnings ratio of -55.90 and a beta of 0.22. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 earnings per share. Analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages recently weighed in on BNTX. TD Cowen reduced their price objective on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. HC Wainwright reiterated a "buy" rating and issued a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Deutsche Bank Aktiengesellschaft raised their price objective on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, September 19th. Bank of America upped their target price on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a report on Monday, September 16th. Finally, UBS Group raised their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a report on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus price target of $140.76.
Check Out Our Latest Report on BNTX
BioNTech Company Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
